2023-2024年中国住院心力衰竭患者现状调查
结果显示HFpEF占比最多,冠心病为最常见病因、诱因及合并症;HFrEF患者预后改善药物使用率高,但器械治疗不足,HFpEF在SGLT2i应用及合并症管理方面有待提升。
要点
- HFpEF占比最多(43.83%),冠心病为最常见病因、诱因及合并症
- HFpEF患者SGLT2i使用率(49.61%)显著低于HFrEF(75.67%)
核心结论
- 我国住院心衰患者中HFpEF占比最多,冠心病是最常见病因、住院诱因及合并症
- HFrEF患者出院时改善预后药物使用率高,但器械治疗应用不足
- HFpEF患者在SGLT2i应用及合并症管理方面仍有较大提升空间
研究设计与样本
- 横断面研究
- 数据来源于中国心力衰竭中心注册研究
主要发现
- 冠心病作为病因、诱因、合并症的比例分别为62.18%、49.36%、65.95%
关键数值与推荐
- HFrEF出院前RASi使用率82.96%,β受体阻滞剂84.77%,MRA 90.57%
- SGLT2i总体使用率61.83%,HFrEF 75.67%,HFmrEF 64.31%,HFpEF 49.61%(P<0.001)
- HFrEF患者CRT-D、CRT-P、ICD植入率分别为1.44%、0.37%、1.35%
- 60岁以下HFpEF血压达标率66.83%,合并冠心病HFpEF心率控制达标率36.46%
临床怎么用
- 临床应重视HFpEF的识别与综合管理,特别是SGLT2i的应用
- 需加强HFrEF患者的器械治疗(CRT、ICD)使用率
- 关注心衰患者冠心病共病的血压与心率管理达标
局限性
- 本研究为横断面设计,无法推断因果关系
- 数据仅来自注册研究,可能存在选择偏倚
- 部分伴随疾病或治疗细节未在摘要中详述
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical characteristics, etiology distribution, comorbidities and treatment strategies of hospitalized patients with heart failure in China from 2023 to 2024. Methods: This was a cross-sectional study. Data were derived from the China Heart Failure Registry. Hospitalized patients with heart failure who participated in the registry between January 1, 2023 and December 31, 2024 were enrolled in this study. According to left ventricular ejection fraction, the enrolled patients were divided into three groups: heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), and heart failure with preserved ejection fraction (HFpEF). Clinical data of patients in each group were collected via a web-based online reporting system, including demographic data, causes of hospitalization, comorbidities, laboratory indicators, electrocardiography findings, echocardiography findings, and treatment strategies. Results: A total of 250 936 heart failure patients were enrolled, with an age of (70.1±13.2) years; among them, 105 338 (41.98%) were female. Specifically, 87 490 cases were diagnosed with HFrEF (34.87%), 53 473 with HFmrEF (21.31%), and 109 973 with HFpEF (43.83%). Coronary heart disease was the most common etiology (62.18%, 156 038/250 936), precipitating factor for hospitalization (49.36%, 123 863/250 936), and comorbidity (65.95%, 165 491/250 936) among hospitalized heart failure patients. Before discharge, the utilization rate of renin-angiotensin system inhibitors was 82.96% (72 578/87 490) in HFrEF patients. The utilization rates of beta-blockers and mineralocorticoid receptor antagonists were 84.77% (74 161/87 490) and 90.57% (79 238/87 490), respectively. The overall utilization rate of sodium-glucose cotransporter 2 inhibitors was 61.83% (155 143/250 936). Stratified by heart failure subtype, the utilization rates were 75.67% (66 195/87 490) in HFrEF patients, 64.31% (34 388/53 473) in HFmrEF patients, and 49.61% (54 560/109 973) in HFpEF patients, with lower rates in HFmrEF and HFpEF patients compared with HFrEF patients (P<0.001). The implantation rates of cardiac resynchronization therapy defibrillators, cardiac resynchronization therapy pacemakers, and implantable cardioverter defibrillators were 1.44% (1 262/87 490), 0.37% (323/87 490), and 1.35% (1 182/87 490), respectively, in HFrEF patients. The blood pressure control rate was 66.83% (8 822/13 201) in HFpEF patients under 60 years old. Among HFpEF patients complicated with coronary heart disease, the heart rate control rate was 36.46% (26 686/73 188). Conclusion: Among hospitalized patients with heart failure in China, HFpEF accounted for the largest proportion. Coronary heart disease was the most common etiology, the leading trigger for hospitalization, and the most prevalent comorbidity in this patient population. At discharge, the utilization rates of prognosis-improving medications remained high in HFrEF patients, whereas the application of device therapy was still insufficient. In HFpEF patients, the use of sodium-glucose cotransporter 2 inhibitors and the management of comorbidities remain areas in urgent need of optimizationin. 目的: 了解2023—2024年中国住院心力衰竭患者的临床特点、病因分布、合并症及治疗情况。 方法: 本研究为横断面研究。数据来源于中国心力衰竭中心注册研究,纳入2023年1月1日至2024年12月31日参与上述研究的住院心力衰竭患者,依据左心室射血分数将纳入患者分为3组:射血分数降低的心力衰竭(HFrEF)、射血分数轻度降低的心力衰竭(HFmrEF)和射血分数保留的心力衰竭(HFpEF)。通过基于网络的在线上报系统收集各组患者的临床资料,包括人口学资料、住院原因、合并症、实验室指标、心电图、超声心动图和治疗情况等。 结果: 共纳入250 936例心力衰竭患者,年龄(70.1±13.2)岁;女性105 338例(41.98%)。HFrEF患者87 490例(34.87%)、HFmrEF患者53 473例(21.31%)、HFpEF患者109 973例(43.83%)。冠心病是住院心力衰竭患者最常见的病因(62.18%,156 038/250 936)、住院诱因(49.36%,123 863/250 936)及合并症(65.95%,165 491/250 936)。出院前,HFrEF患者中肾素-血管紧张素系统抑制剂的使用率为82.96%(72 578/87 490);β受体阻滞剂与盐皮质激素受体拮抗剂的使用率分别为84.77%(74 161/87 490)和90.57%(79 238/87 490)。钠-葡萄糖共转运蛋白-2抑制剂(SGLT2i)的总体使用率为61.83%(155 143/250 936),其中HFrEF、HFmrEF、HFpEF患者的使用率依次为75.67%(66 195/87 490)、64.31%(34 388/53 473)和49.61%(54 560/109 973),HFmrEF、HFpEF组的使用率低于HFpEF组(P<0.001)。HFrEF患者中心脏再同步治疗除颤器、心脏再同步治疗起搏器及埋藏式心脏复律除颤器的植入率分别为1.44%(1 262/87 490)、0.37%(323/87 490)和1.35%(1 182/87 490)。60岁以下HFpEF患者的血压达标率为66.83%(8 822/13 201);合并冠心病的HFpEF患者中,心率控制达标率为36.46%(26 686/73 188)。 结论: 在我国住院心力衰竭患者中,HFpEF占比最多。冠心病是住院心力衰竭患者最常见的病因、住院诱因及合并症。出院时,HFrEF患者使用改善预后的药物的比例较高,但器械治疗应用不足。HFpEF患者在SGLT2i应用及合并症管理方面仍有较大提升空间。.
引用
- Li, Wang, Ji, et al. [Survey on the current status of hospitalized heart failure patients in China, 2023-2024]. Zhonghua Xin Xue Guan Bing Za Zhi. 2026. PMID: 41688181. doi:10.3760/cma.j.cn112148-20251009-00705
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。